| [ Summary ] |
The renin-angiotensin-aldosterone system (RAAS) is activated in cases of chronic kidney disease (CKD) and associated with various CKD-related disorders including abnormal bone metabolism. Animal studies showed that use of an angiotensin Ⅱ type 1 receptor blocker ameliorated kidney damage-induced reduction of bone volume as well as impairment of bone elasticity. In some clinical studies, use of RAAS inhibitors showed reduced incidences of bone fractures in maintenance hemodialysis patients. Use of anti-osteoporotic treatment is limited in CKD patients, especially those undergoing dialysis treatment. Intervention for RAAS may be one of the therapeutic targets for kidney damage-induced abnormal bone metabolism. |